<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004256</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067503</org_study_id>
    <secondary_id>RMNHS-GMCSF</secondary_id>
    <secondary_id>EU-99041</secondary_id>
    <nct_id>NCT00004256</nct_id>
  </id_info>
  <brief_title>Sargramostim to Prevent Mucositis in Patients Receiving Radiation Therapy for Laryngeal Cancer</brief_title>
  <official_title>Randomised Phase II Study of GM-CSF to Reduce Severity of Mucositis Caused by Accelerated Radiotherapy of Laryngeal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as&#xD;
      sargramostim may protect normal cells from the side effects of radiation therapy.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to determine the effectiveness of sargramostim in&#xD;
      preventing mucositis in patients who are receiving radiation therapy for laryngeal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of sargramostim (GM-CSF) in reducing the duration and severity of&#xD;
           mucositis resulting from accelerated radiotherapy in patients with laryngeal carcinoma.&#xD;
&#xD;
        -  Determine the effect of GM-CSF on quality of life aspects of these patients as assessed&#xD;
           by nutritional status, analgesic use, and days in the hospital.&#xD;
&#xD;
      OUTLINE: This is a randomized study.&#xD;
&#xD;
      Patients receive radiotherapy in 16 fractions over 21 days. Patients are randomly allocated&#xD;
      to one of two treatment arms before scheduled radiotherapy begins.&#xD;
&#xD;
        -  Arm I: Patients receive sargramostim (GM-CSF) SC daily for 14 days beginning on day 14&#xD;
           of the course of radiotherapy.&#xD;
&#xD;
        -  Arm II: Patients do not receive GM-CSF. Patients are followed weekly until mucositis is&#xD;
           healed, as well as at weeks 2 and 6 following the end of radiotherapy.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 34 patients (17 per arm) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1997</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <condition>Head and Neck Cancer</condition>
  <condition>Oral Complications</condition>
  <condition>Radiation Toxicity</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of laryngeal cancer with intention to treat by radiotherapy using a 16&#xD;
             fraction 3 week scheme&#xD;
&#xD;
               -  Stage I or II&#xD;
&#xD;
          -  No known CNS disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  20 to 80&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Hepatic function normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Renal function normal&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No serious active infection requiring antibiotic therapy&#xD;
&#xD;
          -  No autoimmune disease&#xD;
&#xD;
          -  No known seizures&#xD;
&#xD;
          -  No psychosocial factors that would preclude study compliance&#xD;
&#xD;
          -  No allergies to sargramostim (GM-CSF)&#xD;
&#xD;
          -  Willingness to cooperate for regular mirror examination of the larynx&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No prior or concurrent corticosteroids&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  No major organ allografts&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J.M. Henk, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Marsden NHS Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>McAleese JJ, Bishop KM, A'Hern R, Henk JM. Randomized phase II study of GM-CSF to reduce mucositis caused by accelerated radiotherapy of laryngeal cancer. Br J Radiol. 2006 Jul;79(943):608-13. doi: 10.1259/bjr/55190439.</citation>
    <PMID>16823067</PMID>
  </results_reference>
  <verification_date>August 2006</verification_date>
  <study_first_submitted>January 28, 2000</study_first_submitted>
  <study_first_submitted_qc>August 22, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2003</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <keyword>stage I laryngeal cancer</keyword>
  <keyword>stage II laryngeal cancer</keyword>
  <keyword>recurrent laryngeal cancer</keyword>
  <keyword>oral complications</keyword>
  <keyword>radiation toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Laryngeal Neoplasms</mesh_term>
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

